super ace super win
Australia's House of Representatives passes bill that would ban young children from social media
The Gophers football program continued to address its needs along the offensive line on Saturday, getting commitments from Washington left tackle Kahlee Tafai and Kentucky left guard Dylan Ray out of the NCAA transfer portal. ADVERTISEMENT The U has four starters leaving after this season, including both tackles — Aireontae Ersery to the NFL Draft and Phillip Daniels in a transfer to Ohio State — and both senior guards Quinn Carroll and Tyler Cooper. The Gophers have added 13 total players through the transfer portal, including right guard Marcellus Marshall (Central Florida). Tafai Tafai, who is listed at 6-foot-5 and 330 pounds, moved into the Huskies’ starting lineup during his freshman season in 2024. He has three years of eligibility remaining. A native of Lawndale, Calif., Tafai played 267 offensive snaps in the Big Ten last season but had a low 38.5 overall grade from Pro Football Focus in his first extensive college experience. He also played a few snaps at right tackle a year ago. ADVERTISEMENT Ray Ray, who is listed at 6-6 and 310, has played more than 1,000 snaps over the last two seasons for Kentucky after beginning his career with two years at West Virginia. He started 10 games for the SEC program in 2023, but only two last year. The Noblesville, Ind., native had a near-average grade of 57.5 from PFF in 2024. He has one year of eligibility remaining for the U next fall. ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .PASSENGERS flying from Birmingham Airport can now travel back in time to the era of a beloved Birmingham-based TV series, with the opening of a new Peaky Blinders-inspired bar and restaurant. The ‘Shelby & Co. Bar and Restaurant’, or ‘Shelby’s’ for short, is the first of its kind in a travel location and will form a key part of Birmingham’s departure lounge with space for 290 diners, the airport has said. In keeping with the era of the popular show, the bar displays the 1920s throughout its design and offers an extensive food and drinks menu that showcases local breweries and gins, providing an authentic taste of Birmingham. The restaurant, which is operated by the SSP Group, has an extensive menu for breakfast, lunch and dinner, offering dishes such as burgers, fish and chips, breakfast classics and bespoke, Brummie-inspired cocktails. The newest food and drink spot at the airport offers both waiter service as well as order-at-table technology, allowing customers short on time to dine quickly. Cathy Granby, Business Development Director for SSP UK & Ireland, said: “Over the past 12 months, one of our key focus areas has been expanding our bespoke airport bar and restaurant concepts. “Shelby & Co. really does bring this hugely popular show to life. “What better way to celebrate all this city has to offer than bringing a flavour of Peaky Blinders to Birmingham Airport.” Richard Gill, Commercial Director of Birmingham Airport, added: “We are delighted to be the first airport to welcome Shelby & Co. “This bespoke, innovative bar and restaurant is a fantastic addition to our departure lounge, ensuring our passengers have a unique chance to sample Shelby’s first-hand when travelling through Birmingham Airport.” It opened earlier this month, on December 18, and aims to provide passengers with “an authentic Peaky Blinder’s experience”.AEW Rampage saw its ratings and audience return to normal without Jake Paul vs. Mike Tyson to worry about. Friday’s show scored in a 0.09 rating in the 18 – 49 demographic and 249,000 viewers per Wrestlenomics . Those numbers were doiwn a tick and 21.5% from the previous week’s 0.06 demo rating and audience of 186,000. The demo rating was the best since the October 25th episode also drew a 0.09, while the viewership was the best since the October 11th episode had 253,000. Like Smackdown , the show was up the NBA game between the Warriors and Pelicans on ESPN, which did a 0.36 demo rating and 1.378 million viewers. Rampage is averaging a 0.100 demo rating and 306,000 viewers in 2024 to date, compared to a 0.118 demo rating and 381,000 for the same point in 2023.
Egyptian President Abdel Fattah Al-Sisi has issued a presidential pardon for 54 convicted individuals from the Sinai Peninsula, according to a statement released on Tuesday by the Egyptian presidency. The pardon was granted “in recognition of the historical role of the people of Sinai in combating terrorism,” the statement said. Presidential spokesperson, Ambassador Mohamed El-Shennawy, stated that President Al-Sisi issued the pardon in accordance with his constitutional authority. The decision also followed a request from representatives, tribal leaders, and elders of Rafah and Sheikh Zuweid in North Sinai, according to the statement. The statement further emphasised that the pardon acknowledges the historical contributions of Sinai residents in counter-terrorism efforts and in promoting development and stability. It also highlighted President Al-Sisi’s concern for the humanitarian circumstances of those convicted in various cases. Ibrahim El-Masry, the Deputy Chairperson of the House of Representatives’ Committee on Defence and National Security, commented that the presidential pardon for the 54 convicted Sinai residents is a significant step towards strengthening the unity of the Egyptian people. He stated that it sends a clear message that the role of Sinai’s people in the fight against terrorism is valued and recognised. El-Masry told parliamentary reporters that the political leadership’s desire to reintegrate the pardoned individuals into society without prejudice is part of the national human rights strategy. He believes that this action contributes to building a society where all its members can meet the challenges facing the nation with strength and courage. He also indicated that this pardon marks the beginning of a positive trend, fostering greater unity and cohesion across all segments of society. He expects future decisions will aim to enhance the participation of all Egyptians in the country’s development. Sheikh Ibrahim Salem, the paramount Sheikh of the South Sinai tribes, praised President Al-Sisi’s decision. He said,”President Al-Sisi is focused on the comprehensive development of Sinai, which is an integral part of Egypt. We hope that President Al-Sisi will continue to look into the cases of detained individuals from Sinai.” Similarly, Sheikh Abdullah Johama, Chairperson of the Sinai Mujahideen Association, also lauded President Al-Sisi’spardon, saying it reflects the political leadership’s appreciation for the historical role of Sinai’s people in protecting the nation. Johama added, “We thank President Al-Sisi for this decision, which demonstrates his commitment to meeting the demands of the people of Sinai and considering the humanitarian aspect. This decision has brought happiness to the affected families and proved that the state does not forget those who stood by its side during the most difficult times.”Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial analysis of bacterial, fungal and viral targets. These new tools enable researchers to customize their assays and panels for use on the QIAcuity digital PCR system as well as on any third-party next-generation sequencing (NGS) system. They also build on more than 700 digital PCR assays that are currently available for microbial targets through the GeneGlobe platform at https://geneglobe.qiagen.com . The new products make nanoplate digital PCR (dPCR) suitable for even more microbial targets in applications ranging from wastewater testing to food production to analysis of human pathogens. With nanoplate dPCR, rare targets in low-biomass samples with high levels of PCR inhibitors can be measured without a standard curve and with high accuracy and precision. “The demands for microbial detection, tracking and scientific research can be extremely specialized. Reliable and accurate tools that can be customized give scientists the flexibility they need to outpace pathogens and accelerate the tempo of discovery,” said Nitin Sood, Senior Vice President and head of QIAGEN’s Life Sciences Business Area. “With the launch of our design tool for Custom dPCR Microbial Assays and the new QIAseq xHXB panels, we are addressing the demands of our customers. QIAGEN will continue to expand our offering of accurate, reliable and easy-to-use solutions.” The new tools are: Design tool for Custom dPCR Microbial Assays – The first-of-its-kind custom assay design tool enables users to design primers and probes for their specific microbial targets of interest and is tailored specifically for bacterial, fungal and viral targets. The design tool software is powered by a sophisticated and thoroughly tested algorithm developed specifically for microbial applications. Researchers can benefit from a user-friendly and intuitive tool that helps them quickly obtain custom assays with optimal sensitivity, specificity and accurate off-target prediction. QIAseq xHYB Custom Microbial Panels – Customers can completely design their own NGS panels, overcoming limitations of panels offered by other vendors, which are designed against a few genomes of a given target and thereby often cause large gaps in coverage. The QIAseq xHYB Custom Microbial Panels advanced algorithm enables researchers to design their assays against many whole genomes at once, allowing them to achieve the highest possible resolution in applications such as microbial detection. QIAGEN continues to expand its portfolio dPCR assays, supporting laboratories to increase their detection capabilities and improve their results. In September, the company added over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications. These newly launched cancer and microbial assays meet the level of quality, multiplexing capabilities, customization, precision and sensitivity associated with all QIAcuity products. Customizable digital PCR assays and the customizable panels and assays are now available on QIAGEN’s GeneGlobe web portal ( https://geneglobe.qiagen.com ), which integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs and pathways. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com . Forward-Looking Statement Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Corporate
STATESVILLE, N.C. , Nov. 27, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its second quarter fiscal year 2025 financial results on Wednesday, December 11, 2024 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Nu Aire Founded in 1971 and based in Minneapolis , the Company is a leading manufacturer of equipment for a diverse range of laboratory and pharmacy environments. Nu Aire is the North American market share leader in biological safety cabinets and other airflow products and also offers a complete line of CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and parts and accessories. Nu Aire's equipment is required for safety and quality in every type of laboratory: life sciences research, clinical, hospital, biotech and pharmaceutical R&D, academia, food and beverage, industrial and more. Nu Aire's website is located at http://www.nuaire.com/ . About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina . Sales offices are located in the United States , India , Saudi Arabia , and Singapore . Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's website is located at http://www.kewaunee.com . This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2024 , which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov . These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Donald T. Gardner III 704/871-3274 View original content to download multimedia: https://www.prnewswire.com/news-releases/kewaunee-scientific-to-report-results-for-second-quarter-fiscal-year-2025-302317861.html SOURCE Kewaunee Scientific CorporationA New Era for Nvidia? Big Surprises Await in 2025Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq